Israel Active

Researchers at the Hebrew University of Jerusalem and Hadassah Medical Center have discovered that the human body’s “natural killer” cells improve their ability to fight diseases affecting the fetus following the first pregnancy. It could lead to new fertility treatments

Israel has launched an $8.4 million p.a. program that enables startups to try out their technologies with the medical data of the four health services. It is part of the National Digital Health plan which aims to make Israel a global leader in digital health technologies.

The Californian healthcare company GRAIL Inc is sponsoring a research program to detect cancer early, led by Hebrew University Professor Yuval Dor. The program will analyze fragmented DNA in the bloodstream that derives from tumors, to identify the type of cancer responsible.

I reported previously on Israel’s MeMed which has developed ImmunoXpert – a fast test to determine whether an infection is bacterial or virus. ImmunoXpert is now EU approved and a recent study shows it can reduce unnecessary antibiotic use by nearly 90%.

Israeli startup PulseNmore.is completing development of a revolutionary handheld ultrasound device that will allow pregnant women to check on the health of their baby using a smartphone. On its website, PulseNmore says it’s in stealth mode, so shhh! this new “baby” is asleep.

I reported previously that Ben Gurion University Professor Varda Shoshan-Barmatz had discovered that suppressing the protein VDAC1 inhibits tumor growth. Her team’s latest research shows that small interfering ribonucleic acids (siRNAs) can reprogram the cancer cells back to normal-like cells.  Ointment for pre-skin cancer is in Phase 2 trials.

Researchers at Israel’s Ben-Gurion University are developing a new, single-dose fertility treatment based on a new telomerase-activating compound, which can improve both male and female fertility. It can also help protect the fertility of cancer patients undergoing radiation therapy.

The US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), is sponsoring a US-wide Phase 2 trial of the M-001 Universal Flu vaccine from Israel’s BiondVax.  A 9,630-person, EU-financed Phase 3 trial is already scheduled.

Five Israeli bio-techs at Israel’s MIXiii-Biomed 2018 are developing new therapies for “orphan” (rare) genetic diseases. They include ART Bioscience (Duchenne’s), Eloxx (cystinosis), SpliSense (Cystic Fibrosis), NewStem (Fragile X Syndrome) and Minovia (mitochondrial diseases).  

Israel’s Genoox employs machine learning algorithms to analyze large amounts of genetic data, helping doctors and clinicians to personalize treatment and researchers to develop new therapies. Genoox was selected by Israel’s Ministry of Health for its 100,000 Genome Project.